Bertram Pitt

Jan 17, 2025 | onlinelibrary.wiley.com | Robert J. Mentz |Stefan Anker |Bertram Pitt |Peter Rossing

Supporting Information Filename Description ejhf3569-sup-0001-Supinfo.docxWord 2007 document , 620.3 KB Appendix S1. Supporting Information. References 1, , . Detecting and treating lung congestion with kidney failure. Clin J Am Soc Nephrol 2022; 17: 757–765. https://doi.org/10.2215/cjn.14591121 2, , , . Volume overload and adverse outcomes in chronic kidney disease: Clinical observational and animal studies. J Am Heart Assoc 2015; 4:e001918.

May 14, 2024 | onlinelibrary.wiley.com | Muthiah Vaduganathan |Brian Claggett |Carolyn S.P. Lam |Bertram Pitt

Introduction Activation of the mineralocorticoid receptor (MR) by aldosterone has long been recognized as a central driver of heart failure (HF) pathogenesis.1 Mechanistically, ligand binding to the nuclear MR triggers a diverse signalling cascade contributing to excess salt and water retention, systemic hypertension, endothelial dysfunction, and pathological fibrosis, hypertrophy, and inflammation of the end organs, including the heart and kidneys.2 These core mechanisms of disease...

Feb 23, 2024 | onlinelibrary.wiley.com | Bertram Pitt |H. David Humes

Introduction Despite current therapy of patients hospitalized with acute (AHF) or worsening (WHF) heart failure, both heart failure with a reduced ejection fraction (HFrEF) and a preserved ejection fraction (HFpEF), there remains a relatively high incidence of cardiovascular (CV) mortality and hospitalizations for HF (HHF) at 30 and 90 days post-admission and/or discharge.1 The administration of sodium–glucose cotransporter inhibitors prior to and or shortly after discharge for AHF or WHF is...

Feb 5, 2024 | ahajournals.org | Bertram Pitt |Gordon Williams

REFERENCES1. Brown JM, Siddiqui M, Calhoun DA, Carey RM, Hopkins PN, Williams GH, Vaidya A. The unrecognized prevalence of primary aldosteronism: a cross-sectional study.Ann Intern Med. 2020; 173:10–20. doi: 10.7326/M20-0065CrossrefMedlineGoogle Scholar2. Bauersachs J, Jaisser F, Toto R. Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal disease.Hypertension. 2015; 65:257–263. doi: 10.1161/HYPERTENSIONAHA.114.04488LinkGoogle Scholar3.

Jan 18, 2024 | onlinelibrary.wiley.com | Bertram Pitt |Jenifer M. Brown |Anand Jayprakash Vaidya |Javier Diez

Corresponding Author Javier Diez Center for Applied Medical Research (CIMA), and School of Medicine, University of Navarra, Pamplona, Spain Center for Network Biomedical Research of Cardiovascular Diseases (CIBERCV), Carlos III Institute of Health, Madrid, Spain Corresponding author. Edificio CIMA, Av Pío XII 55, 31008 Pamplona, Spain. Email: [email protected] for more papers by this author